Spondyloarthritis Overview

Principles

Definition

Spondyloarthritis is a clinical and research classification encompassing a family of chronic inflammatory rheumatic diseases unified by shared clinical features, genetic associations (notably HLA-B27), and pathological mechanisms primarily involving inflammation at the entheses and axial skeleton. Research within this concept investigates the diverse clinical spectrum, pathogenesis, diagnosis, and therapeutic approaches across this group of conditions, aiming to advance understanding and management of inflammatory arthropathies.

Ontological type

Pathophysiology

Therapeutic Management

Diagnostic Strategies

Key developments

Key Figures

HLA Immunogenetic Foundation era

Frank C. Arnett [1] was a leading figure at Stanford University [3] and Johns Hopkins University [4] during the early HLA-based immunogenetic investigations of spondyloarthritis. His key contributions, including the papers Hla-c locus antigens in hla-b27 associated arthritis [6] and The Implications of HL-A W27 [7], established the HLA-B27 association as a unifying marker and provided the methodological foundation for genotype-informed diagnostic concepts in this era. Marc C. Hochberg [2] worked with Johns Hopkins University [4] and the University of Miami [5] during this period, contributing to the HLA-centered framework through the 1978 paper Hla-c locus antigens in hla-b27 associated arthritis [6]. The collaborative emphasis at Johns Hopkins University [4] and University of Miami [5] helped seed population-level carrier concepts and risk stratification that underpinned the immunogenetic approach to spondyloarthritis in this era.

Standardization and TNF Era era

Joachim Sieper [1] is a prominent rheumatologist affiliated with Université Paris Cité [3] and the University of Birmingham [4] during the Standardization and TNF Era. His contributions include the randomized multicentre trial Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial [7], and the Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors [8], which advanced standardized trial designs and phenotype concepts essential to this era. Jürgen Braun [2] was affiliated with Technical University of Munich [5] and Franklin University [6] during this era. His contributions include the infliximab trial [7], illustrating TNF blockade's central role in disease management, and the Age at disease onset and diagnosis delay in HLA-B27 negative vs positive patients [9], which highlighted diagnostic timing and phenotyping needs within the standardized framework.

Molecular-Imaging Targeted Therapy era

Walter P. Maksymowych [1] is a prominent rheumatologist whose work spanned the University of California, San Francisco [3] and the University of Pennsylvania [4] during the Molecular-Imaging Targeted Therapy era. His key contributions include the Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci [6], the 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [7], and Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial [8], collectively advancing genetic insights, guideline-driven care, and targeted IL-17 therapy in axial spondyloarthritis. Michael M. Ward [2] has been affiliated with the University of California, San Francisco [3] and Johns Hopkins University [5] during this era. His contributions include the Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci [6] and the 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis [7], shaping understanding of genetic risk and informing evidence-based, phenotype-guided therapy in axial spondyloarthritis.